Pancreatic Cancer Research

ResearcherMoffitt Cancer CenterActive in the last 2 years

Song Gao

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-4587-5527; OpenAlex author ID A5101448416. Sources: ClinicalTrials.gov.

Their work

Papers
53 (first author 5, last author 5)
Trials
2 (principal investigator on 2)
Grants
0
Labs led
1
Collaborators
104
Papers, trials and grants by year

2012: 2 papers · 2013: 1 paper · 2014: 6 papers · 2015: 3 papers · 2016: 4 papers · 2017: 2 papers · 2018: 2 papers · 2019: 1 paper · 2020: 1 paper · 2021: 4 papers · 2022: 5 papers · 2023: 9 papers, 1 trial · 2024: 6 papers · 2025: 4 papers · 2026: 3 papers, 1 trial

Papers 50 of 53

  1. NALIRIFOX versus gemcitabine plus nab-paclitaxel in Chinese patients with advanced pancreatic adenocarcinoma: a randomized, open-label phase II trial. Co-author DOI 10.1038/s41467-026-68409-0↗
  2. Trogocytosis-orchestrated CLDN18.2-"dressed" CD8+ T cells drive pancreatic cancer progression via glucose metabolic reprogramming-induced cytotoxicity debilita… Co-author DOI 10.1136/gutjnl-2025-335790↗
  3. Senescent Cancer-Associated Fibroblasts Drive Early-Stage Lymph Node Metastasis in Pancreatic Cancer through Lactate-Mediated Metabolic-Epigenetic Rewiring. Co-author DOI 10.1158/2159-8290.cd-25-1627↗
  4. A Preoperative Model for Predicting Lymphovascular Invasion in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1016/j.jss.2025.06.081↗
  5. A CD147-targeted small-molecule inhibitor potentiates gemcitabine efficacy by triggering ferroptosis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.xcrm.2025.102292↗
  6. Targeting TNK2/ACK1 reverses the immunosuppressive tumor microenvironment and synergizes with immunochemotherapy in pancreatic cancer. Co-author DOI 10.1038/s41467-025-67197-3↗
  7. Integrated pretreatment stratification system for pancreatic cancer: combining anatomical resectability and tumor biological parameters. Co-author DOI 10.20892/j.issn.2095-3941.2025.0213↗
  8. Tumor-derived interleukin 35 mediates the dissemination of gemcitabine resistance in pancreatic adenocarcinoma. Co-author DOI 10.1038/s41388-024-02938-0↗
  9. Correction: BICC1 drives pancreatic cancer progression by inducing VEGF-independent angiogenesis. Co-author DOI 10.1038/s41392-023-01721-z↗
  10. Nomogram model for predicting early recurrence for resectable pancreatic cancer: A multicenter study. Last author DOI 10.1097/md.0000000000037440↗
  11. BICC1 drives pancreatic cancer stemness and chemoresistance by facilitating tryptophan metabolism. Co-author DOI 10.1126/sciadv.adj8650↗
  12. CD64+ fibroblast-targeted vilanterol and a STING agonist augment CLDN18.2 BiTEs efficacy against pancreatic cancer by reducing desmoplasia and enriching stem-l… Co-author DOI 10.1136/gutjnl-2024-332371↗
  13. Fibrinogen to pre-albumin ratio is an independent prognostic index for patients with pancreatic ductal adenocarcinoma after radical resection. Last author DOI 10.1186/s12957-024-03524-0↗
  14. A new staging system for postoperative prognostication in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.isci.2023.107589↗
  15. BICC1 drives pancreatic cancer progression by inducing VEGF-independent angiogenesis. Co-author DOI 10.1038/s41392-023-01478-5↗
  16. Selective extended dissection for pancreaticoduodenectomy is associated with better survival in pancreatic cancer patients: retrospective cohort study. Last author DOI 10.1097/js9.0000000000000437↗
  17. SDCBP promotes pancreatic cancer progression by preventing YAP1 from β-TrCP-mediated proteasomal degradation. Co-author DOI 10.1136/gutjnl-2022-327492↗
  18. Irbesartan overcomes gemcitabine resistance in pancreatic cancer by suppressing stemness and iron metabolism via inhibition of the Hippo/YAP1/c-Jun axis. Co-author DOI 10.1186/s13046-023-02671-8↗
  19. Nuclear PLD1 combined with NPM1 induces gemcitabine resistance through tumorigenic IL7R in pancreatic adenocarcinoma. Co-author DOI 10.20892/j.issn.2095-3941.2023.0039↗
  20. The role of BHLHE40 in clinical features and prognosis value of PDAC by comprehensive analysis and in vitro validation. Co-author DOI 10.3389/fonc.2023.1151321↗
  21. Comparison of adjuvant nab-paclitaxel plus gemcitabine, S-1 and gemcitabine chemotherapy for resectable pancreatic cancer: a real-world study. Co-author DOI 10.3389/fonc.2023.1276037↗
  22. Presence of tumor deposits is an indicator of poor prognosis in patients with pancreatic ductal adenocarcinoma. Last author PMID 37293176↗
  23. Genome-wide CRISPR screen identifies MTA3 as an inducer of gemcitabine resistance in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2022.215864↗
  24. ESE3-positive PSCs drive pancreatic cancer fibrosis, chemoresistance and poor prognosis via tumour-stromal IL-1β/NF-κB/ESE3 signalling axis. Co-author DOI 10.1038/s41416-022-01927-y↗
  25. BZW1 Facilitates Glycolysis and Promotes Tumor Growth in Pancreatic Ductal Adenocarcinoma Through Potentiating eIF2α Phosphorylation. Co-author DOI 10.1053/j.gastro.2021.12.249↗
  26. ESE3/EHF, a promising target of rosiglitazone, suppresses pancreatic cancer stemness by downregulating CXCR4. Co-author DOI 10.1136/gutjnl-2020-321952↗
  27. SOX8 Affects Tumoral SPARC Expression by Regulating EZH2 to Attenuate Effectiveness of albumin-bound paclitaxel in PDAC. Co-author DOI 10.7150/ijbs.64752↗
  28. Serum insulin-like growth factor binding protein 2 levels as biomarker for pancreatic ductal adenocarcinoma-associated malnutrition and muscle wasting. Co-author DOI 10.1002/jcsm.12692↗
  29. PERK-eIF2α-ERK1/2 axis drives mesenchymal-endothelial transition of cancer-associated fibroblasts in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2021.05.021↗
  30. CD73 induces gemcitabine resistance in pancreatic ductal adenocarcinoma: A promising target with non-canonical mechanisms. Co-author DOI 10.1016/j.canlet.2021.07.024↗
  31. Delta HU is a potential marker to predict chemotherapy response for unresectable pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.pan.2021.02.016↗
  32. IL-37/ STAT3/ HIF-1α negative feedback signaling drives gemcitabine resistance in pancreatic cancer. Co-author DOI 10.7150/thno.42416↗
  33. Tumoral EHF predicts the efficacy of anti-PD1 therapy in pancreatic ductal adenocarcinoma. Co-author DOI 10.1084/jem.20180749↗
  34. Interleukin 35 Expression Correlates With Microvessel Density in Pancreatic Ductal Adenocarcinoma, Recruits Monocytes, and Promotes Growth and Angiogenesis of … Co-author DOI 10.1053/j.gastro.2017.09.039↗
  35. Effects of baicalein on pancreatic cancer stem cells via modulation of sonic Hedgehog pathway. Co-author DOI 10.1093/abbs/gmy045↗
  36. Babaodan Capsule () combined with Qingyi Huaji Formula () in advanced pancreatic cancer-a feasibility study. First author DOI 10.1007/s11655-017-2279-1↗
  37. Detection of Circulating Tumor Cells Using Negative Enrichment Immunofluorescence and an In Situ Hybridization System in Pancreatic Cancer. Co-author DOI 10.3390/ijms18040622↗
  38. Ski modulate the characteristics of pancreatic cancer stem cells via regulating sonic hedgehog signaling pathway. Co-author DOI 10.1007/s13277-016-5461-8↗
  39. Nanog Predicts Poor Prognosis in Human Pancreatic Cancer and Is Downregulated by QingyihuaJi Formula in Pancreatic Cancer Stem Cells. Co-author DOI 10.1155/2016/7028289↗
  40. IGFBP2 Activates the NF-κB Pathway to Drive Epithelial-Mesenchymal Transition and Invasive Character in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/0008-5472.can-16-0438↗
  41. ROR functions as a ceRNA to regulate Nanog expression by sponging miR-145 and predicts poor prognosis in pancreatic cancer. Co-author DOI 10.18632/oncotarget.6450↗
  42. LASP1 is a HIF1α target gene critical for metastasis of pancreatic cancer. Co-author DOI 10.1158/0008-5472.can-14-2040↗
  43. Inhibition of HIF-1α by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/oncotarget.2948↗
  44. Establishment of a pancreatic cancer stem cell model using the SW1990 human pancreatic cancer cell line in nude mice. First author DOI 10.7314/apjcp.2015.16.2.437↗
  45. The clinical significance and regulation mechanism of hypoxia-inducible factor-1 and miR-191 expression in pancreatic cancer. Co-author DOI 10.1007/s13277-014-2452-5↗
  46. The outcome of cryoablation in treating advanced pancreatic cancer: a comparison with palliative bypass surgery alone. Co-author DOI 10.1111/1751-2980.12170↗
  47. MicroRNA expression in salivary supernatant of patients with pancreatic cancer and its relationship with ZHENG. Co-author DOI 10.1155/2014/756347↗
  48. Hypoxia-inducible factor-1 promotes pancreatic ductal adenocarcinoma invasion and metastasis by activating transcription of the actin-bundling protein fascin. First author DOI 10.1158/0008-5472.can-13-3009↗
  49. CypA, a gene downstream of HIF-1α, promotes the development of PDAC. Co-author DOI 10.1371/journal.pone.0092824↗
  50. [Effects of dioscin on apoptosis in pancreatic cancer MiaPaCa-2 cells and its mechanism]. Co-author PMID 24685079↗

Trials 2

  1. Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Therapy for High - Risk Resectable or Borderline Resectable … Principal investigator NCT07436741↗
  2. Efficacy and Safety of Surufatinib Combined With Gemcitabine and Albumin-bound Paclitaxel in the Peri-operative Treatment of Pancreatic Cancer Principal investigator NCT05908747↗

Closest collaborators

The 25 strongest of 104 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jihui Hao · 37 shared papers, 2 shared trials, 2012–2026 · strength 6.08
  2. Xiuchao Wang · 29 shared papers, 2012–2026 · strength 3.68
  3. Tiansuo Zhao · 28 shared papers, 2012–2026 · strength 3.61
  4. Chongbiao Huang · 24 shared papers, 2015–2026 · strength 3.30
  5. Shengyu Yang · 18 shared papers, 2014–2026 · strength 2.35
  6. Jing Liu · 16 shared papers, 2014–2026 · strength 2.19
  7. Yuexiang Liang · 6 shared papers, 2023–2025 · strength 1.43
  8. Shaofei Chang · 6 shared papers, 2023–2025 · strength 1.32
  9. Yiping Zou · 6 shared papers, 2023–2025 · strength 1.29
  10. Tianxing Zhou · 8 shared papers, 2019–2026 · strength 1.23
  11. Yongjie Xie · 7 shared papers, 2022–2026 · strength 1.15
  12. Quan Man · 5 shared papers, 2023–2025 · strength 1.02
  13. Chuntao Gao · 8 shared papers, 2014–2026 · strength 0.97
  14. Yukuan Feng · 5 shared papers, 2024–2026 · strength 0.96
  15. Huizhi Sun · 6 shared papers, 2021–2024 · strength 0.91
  16. Jun Yu · 4 shared papers, 2024–2026 · strength 0.77
  17. Zengxun Li · 5 shared papers, 2018–2024 · strength 0.71
  18. Danqi Fu · 5 shared papers, 2019–2024 · strength 0.65
  19. Wenna Jiang · 5 shared papers, 2019–2024 · strength 0.62
  20. Chao Yang · 3 shared papers, 2025–2026 · strength 0.60
  21. Chao Xu · 4 shared papers, 2017–2024 · strength 0.55
  22. He Ren · 8 shared papers, 2012–2019 · strength 0.44
  23. Yifei Wang · 2 shared papers, 2026 · strength 0.42
  24. Shangheng Shi · 2 shared papers, 2026 · strength 0.42
  25. Rui Liu · 2 shared papers, 2026 · strength 0.40

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.